Liminatus Pharma risks Nasdaq delisting after missing key financial targets
Liminatus Pharma, Inc. (LIMN) faces delisting from Nasdaq after failing to meet key financial thresholds. The company missed both the $50 million market capitalisation and $15 million public float requirements by the May 18 deadline. Investors have reacted with sharp price swings, reflecting uncertainty over the stock’s future.
Nasdaq’s listing rules demand a minimum $50 million market value for listed securities, as outlined in Rule 5450(b)(2)(A). LIMN failed to reach this benchmark before the compliance deadline. The company also fell short of the $15 million public float requirement under Rule 5450(b)(2)(C), despite a 180-day grace period.
Trading in LIMN shares has become highly volatile since the delisting announcement. At one point, the stock surged by 31%, only to drop again as investors weighed the risks. If no appeal is submitted, Nasdaq will halt trading on May 29, 2026. Liminatus still has a narrow window to challenge the decision. The firm must file an appeal by May 27, 2026, to avoid removal from the exchange.
The company’s failure to meet Nasdaq’s financial standards has triggered market instability. Without a successful appeal, LIMN shares will cease trading at the end of May. The outcome will determine whether the stock remains accessible to public investors.
